EXHIBIT 10(z) ENZO DIAGNOSTICS, INC. - AMERSHAM INTERNATIONAL PLC DISTRIBUTORSHIP AGREEMENT THIS AGREEMENT, effective upon acceptance by both parties below by and between ENZO DIAGNOSTICS, INC. ("ENZO"), a New York corporation having its principal place of business at 60 Executive Boulevard, Farmingdale, New York 11735, U.S.A., and AMERSHAM INTERNATIONAL public limited company ("AMERSHAM") a company incorporated in England and Wales, having its principal place of business at Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, England. WHEREAS, ENZO owns rights to certain PATENTS listed in EXHIBIT A ("PATENTS"); WHEREAS ENZO manufactures and/or sells certain PRODUCTS ("PRODUCT(S)") covered by claims of PATENTS; WHEREAS AMERSHAM wishes to market and distribute some of said PRODUCTS as listed in EXHIBIT B; NOW, THEREFORE, in consideration of the good and valuable mutual agreements hereinafter set forth, the parties hereto agree as follows: DEFINITIONS: AMERSHAM Affiliate means an entity controlled by or under common control with AMERSHAM, including United States Biochemical Corporation (USB), as listed in EXHIBIT C. For purposes of this AGREEMENT, control shall mean the ownership of a majority of the voting equity interest. AMERSHAM Distributor means a local company, outside the countries listed in EXHIBIT C, in which AMERSHAM does not sell directly or through an AMERSHAM Affiliate. AMERSHAM Distributors do not have rights to sell in the countries listed in EXHIBIT C. AMERSHAM means AMERSHAM International, including USB, AMERSHAM Affiliates and AMERSHAM Distributors. PRODUCT means an individual reagent or combination of reagents (kit) that are, individually or combined, covered by ENZO PATENTS (EXHIBIT A) as listed in EXHIBIT B. COMPONENT, listed in EXHIBIT D, means a reagent that is a necessary part of the PRODUCT. COMPONENT 1 means a COMPONENT, as listed in EXHIBIT E, that is covered by ENZO PATENT(S) and by AMERSHAM patent(s) either assigned or licensed to AMERSHAM and not sublicensed to a third party for Life Science research use (not an AMERSHAM Affiliate or AMERSHAM Distributor as defined above and as listed in EXHIBIT C). 1. Distributor Appointment 1.1 ENZO hereby appoints AMERSHAM to act as its nonexclusive distributor worldwide for the distribution and sale of PRODUCTS through AMERSHAM Affiliates listed in EXHIBIT C, and AMERSHAM Distributors and AMERSHAM agrees to act as such distributor under the terms and conditions set forth herein. 1.2 AMERSHAM agrees: a. not to purchase any PRODUCTS from other suppliers; b. not to manufacture PRODUCTS, except as otherwise stated in this AGREEMENT; c. to rely on ENZO as its sole source of PRODUCTS; d. not to use any PRODUCT to manufacture new products or other PRODUCTS, except when designated by ENZO to manufacture such PRODUCTS for ENZO as provided in Paragraph 3.3 below; e. that all PRODUCTS sold by AMERSHAM are for research use only and are not intended for or to be used for diagnostic or therapeutic purposes; and f. that except for DISTRIBUTION under the terms and conditions as set forth in this AGREEMENT, purchase does not include any right or license to exploit these PRODUCTS commercially, including any right to sell these PRODUCTS to other distributors who are not AMERSHAM Affiliates or AMERSHAM Distributors (EXHIBIT C) and - 2 - that any commercial use or development of these PRODUCTS without the express written authorization of ENZO is strictly prohibited. 2. Relationship between ENZO and AMERSHAM 2.1 Nothing herein creates or constitutes a partnership or an agreement of agency between the parties with respect to any activities whatsoever. The relationship between ENZO and AMERSHAM shall be that of seller and buyer, and neither party shall conclude any contract or agreement or make any commitment, representation or warranty which binds the other party or otherwise acts in the name of or on behalf of the other party. 2.2 This AGREEMENT may not be assigned or otherwise transferred by AMERSHAM without the prior written consent of ENZO. Any attempted assignment or transfer without such consent shall be void. 2.3 AMERSHAM agrees that it has manufactured and sold in the past a range of COMPONENTS, COMPONENTS 1 and PRODUCTS and maintains in its current inventory the aforementioned COMPONENTS, COMPONENTS 1 and PRODUCTS all as set forth in EXHIBIT F. AMERSHAM agrees that it will * . ENZO agrees that * will be applied as full consideration for satisfaction of damages incurred by ENZO arising from the past manufacture, use and sale of said COMPONENTS, COMPONENTS 1 and PRODUCTS by AMERSHAM, AMERSHAM Affiliates and AMERSHAM Distributors. 2.4 ENZO and AMERSHAM agree that the distribution relationship between them does not constitute, nor does it imply a license of any of ENZO's technology or patents, nor does it abrogate any of ENZO's rights under its patents. ENZO maintains full rights under its PATENTS. The foregoing statements are paramount to this AGREEMENT. 3. PRODUCTS, Price and Payment 3.1 PRODUCTS covered by this Agreement are listed in EXHIBIT B attached hereto. The price to AMERSHAM for each product shall be as listed in - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 3 - EXHIBIT B. Prices are based upon * Prices to AMERSHAM may be adjusted no more than once during a calendar year. ENZO has the right to negotiate to adjust prices to AMERSHAM after providing AMERSHAM with forty-five (45) days written notice. Any price adjustment will affect future purchases, but will not affect those already under existing firm purchase order commitment. AMERSHAM shall be free to set all resale prices to its customers. 3.2 ENZO or AMERSHAM may propose in writing to add, to modify or to delete a PRODUCT or PRODUCTS in EXHIBIT B. Both ENZO and AMERSHAM must agree to such additions to, deletions from or modifications of PRODUCTS in EXHIBIT B before such additions, deletions or modifications are incorporated therein. 3.3 Upon signing of this AGREEMENT, ENZO designates AMERSHAM to * 3.4 ENZO, may, at its discretion, and for a specified period of time, designate AMERSHAM as an interim manufacturer to manufacture certain * certain PRODUCTS, including the corresponding packaging, other than those specified by Paragraph 3.3 for ENZO. These * PRODUCTS and prices to ENZO are listed in EXHIBIT D. Upon * written notice to AMERSHAM, ENZO may either manufacture * PRODUCT(s) or may designate an alternate manufacturer. 3.5 Whenever prices for PRODUCTS are adjusted, prices of COMPONENTS may be adjusted upon mutual agreement of the parties; the ratio of COMPONENT price to PRODUCT price will not increase. 4. Terms of Payment and Audit 4.1 Net, thirty (30) days from the end of the month in which the PRODUCTS are delivered to AMERSHAM. - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 4 - 4.2 Net, thirty (30) days from the end of the month in which the COMPONENTs are delivered to ENZO. 4.3 AMERSHAM agrees to permit its books and records to be examined by ENZO on reasonable prior notice, as necessary, but not more often than once per year to verify receipts. Such examination is to be made by ENZO, at ENZO's expense, except in the event that the results of the audit reveal a discrepancy benefiting ENZO by * then the audit fees shall be paid by AMERSHAM. 5. PRODUCT Shipments 5.1 ALL PRODUCTS shipped by ENZO to AMERSHAM will be shipped F.O.B. Farmingdale, NY. ENZO shall ensure PRODUCTS are suitably, safely and securely packaged and labeled before dispatch. 5.2 ALL COMPONENTS shipped by AMERSHAM to ENZO will be shipped F.O.B. Cardiff Laboratories, Wales. AMERSHAM shall ensure COMPONENTS are suitably, safely and securely packaged and labeled before dispatch. 6. Forecasts and Purchase Orders 6.1 AMERSHAM shall issue a forecast schedule during the mid-month of each calendar quarter covering its estimated requirements for PRODUCTS for the succeeding two (2) calendar quarters. Such forecast shall be considered for planning purposes only and do not represent a purchase commitment. 6.2 A purchase order will be issued by AMERSHAM at least sixty (60) days in advance of the requested delivery date of PRODUCT. This purchase order will indicate specific delivery and/or shipping requirements. Purchase orders will be delivered to ENZO by Federal Express or similar carrier so that the receipt can be confirmed. ENZO shall meet such requirements unless it advises AMERSHAM within * of the date of the receipt of such purchase order that it is unable to supply PRODUCT as ordered by AMERSHAM whereupon the parties agree to discuss a revised schedule for delivery of PRODUCT to AMERSHAM. After ENZO and AMERSHAM have agreed to the provisions of a revised schedule, ENZO will make its best efforts to fulfill the provisions of the revised schedule, but if unable to do so - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 5 - or if agreement on a revised schedule cannot be reached, ENZO by good faith effort will designate AMERSHAM as an interim or temporary manufacturer for such PRODUCT for ENZO until such time as ENZO gives AMERSHAM written notice that ENZO is ready to recommence supply. 6.3 ENZO shall place orders for COMPONENTS within fourteen (14) days following receipt of AMERSHAM's purchase order for PRODUCTS. COMPONENTS shall comply with the written specification therefor supplied by AMERSHAM with COMPONENTS. ALL OTHER WARRANTIES EXPRESS OR IMPLIED INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY EXCLUDED. 6.4 Each purchase order shall be governed by the relevant provisions of this AGREEMENT (unless otherwise expressly provided in the individual purchase order and confirmed in writing by ENZO) and no term or condition which may appear in the printed matter in AMERSHAM's order form or any form from ENZO shall be binding on either party or apply to any transaction under this AGREEMENT. 7. PRODUCT Deliveries and Specifications 7.1 Within about forty five (45) days after the effective date of this AGREEMENT, ENZO and AMERSHAM shall agree on PRODUCT specifications and package inserts for the PRODUCTS which shall otherwise be in the form set out in EXHIBIT B. Quality Control (QC) specifications for the PRODUCTS in EXHIBIT B, to be agreed upon by ENZO and AMERSHAM, are also listed in EXHIBIT B. 7.2 When an order is placed by AMERSHAM, ENZO shall ship the PRODUCT in accordance with section 5 above. Failure by AMERSHAM to notify ENZO of rejection of the PRODUCT within * of receipt of PRODUCT will constitute acceptance. ENZO shall supply, at the time of shipment of the PRODUCT to AMERSHAM, a statement that the PRODUCT conforms to the PRODUCT specifications. If after receipt of the PRODUCT, AMERSHAM determines that it does not conform to the PRODUCT specifications provided by ENZO, and that the failure to conform to the PRODUCT specifications was not the result of shipping and handling or quality of COMPONENTS delivered by AMERSHAM, AMERSHAM will provide ENZO with - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 6 - documentation of this failure to conform to the PRODUCT specifications. If ENZO accepts the documentation provided by AMERSHAM, ENZO will replace the order. If ENZO does not accept the documentation provided by AMERSHAM, then the differences in the determination of the manufacturing specifications will be settled by representatives of the technical staffs of ENZO and AMERSHAM. 7.3 If AMERSHAM receives a notice from a third party asserting that any of the PRODUCTS infringe on an issued patent in the country in which they are sold, then AMERSHAM shall immediately give notice to ENZO. Upon notice to ENZO or AMERSHAM from a third party asserting that any of the PRODUCTS of this AGREEMENT infringe on an issued patent in the country in which such PRODUCTS are sold, ENZO has the right to exclude such PRODUCTS from this AGREEMENT for that country and can further instruct AMERSHAM to cease all such distribution of such PRODUCT in that country. Further distribution of PRODUCTS after such instruction from ENZO to AMERSHAM will be at the sole risk of AMERSHAM and AMERSHAM shall indemnify and hold harmless ENZO from all infringement liability and damages with respect to such PRODUCTS, including legal costs, compensatory and punitive damages, and attorneys fees. 7.3.1 ENZO will use its best efforts to obtain a license under commercially reasonable terms from any such third party asserting patents as described in Paragraph 7.3. In this event ENZO has the right to adjust prices to AMERSHAM to reflect the licensing cost and ENZO and AMERSHAM will negotiate in good faith to arrive at the amended price. 7.3.2 In the absence of instructions from ENZO to cease sales, ENZO will indemnify AMERSHAM against claims or proceedings for infringements. 7.3.3 Notwithstanding any third party infringement claims, all provisions of this AGREEMENT, including Section 7, shall not be affected but shall remain in full force and effect. 8. Sales Promotions 8.1 AMERSHAM shall use its best efforts in sales promotions and advertisement of the PRODUCTS such as direct mailings, direct customer contact, catalog listings and trade meeting promotions. ENZO will provide AMERSHAM with one copy of the literature, technical data, specifications and the like describing the PRODUCTS as they are currently produced for the assistance of AMERSHAM in the preparation of advertising, catalog and other sales and promotional material. AMERSHAM will list PRODUCTS in its next available - 7 - or published product catalog(s) in which the PRODUCTS can be listed and continued such listing after the effective date of this AGREEMENT. AMERSHAM will modify the listings of PRODUCTS in its product catalog(s) as soon as reasonably possible after any corresponding modification of the list of such PRODUCTS in EXHIBIT B. 9. PRODUCT Warranty 9.1 ENZO warrants that the PRODUCTS sold by ENZO to AMERSHAM shall meet the specifications accompanying the PRODUCT delivery. ENZO's sole obligation is to replace the PRODUCTS or give credit therefor to the extent of the purchase price. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 9.2 ENZO further warrants that all relevant quality control tests and quality assurance procedures will be performed for each batch of PRODUCTS so that each batch of PRODUCT conforms with the Product Specifications as listed in EXHIBIT B, that the PRODUCTS will be contained, packaged and labeled as specified by the Product Specifications for such PRODUCTS and that the PRODUCTS will comply with product safety regulations as indicated in EXHIBIT G. 10. Storage and Stock Rotation 10.1 ENZO agrees to share with AMERSHAM all necessary storage and stock rotation practices which apply to the PRODUCTS. 10.2 AMERSHAM further agrees to take diligent care not to ship PRODUCTS to its customers which have expired, been damaged in storage or handling, or improperly stored. AMERSHAM will be responsible for damages arising from its shipment of expired, damaged, or improperly stored PRODUCTS. - 8 - 11. PRODUCT Labels 11.1 AMERSHAM agrees to ship all PRODUCTS with a joint PRODUCT label which prominently includes the name ENZO DIAGNOSTICS, INC. and AMERSHAM INTERNATIONAL plc with their respective company logos where appropriate. AMERSHAM further agrees to ship all PRODUCTS intact with ENZO's package inserts and any notice(s) appearing thereon. 12. Force Majeure 12. No liability shall result to either party from delay in performance or from nonperformance under this AGREEMENT caused by circumstances beyond the control of the party who has delayed performance or not performed. The nonperforming party shall be diligent in attempting to remove any such cause and shall promptly notify the other party of its extent and probable duration. 13. Duration and Termination 13.1 This AGREEMENT shall become effective as of the date hereinabove written and shall continue for a period of *. Unless terminated, it will continue thereafter for successive renewal terms of *. Notwithstanding such period or any renewal, either party may terminate this AGREEMENT without cause at any time by giving the other party notice in writing at least * in advance of the effective termination date stated in such notice. 13.2 Upon termination of this AGREEMENT all rights, including distribution rights to AMERSHAM and AMERSHAM Affiliates and AMERSHAM Distributors (EXHIBIT C) will be deemed canceled and returned to ENZO. 14. Confidentiality 14.1 Each party undertakes to keep secret and not disclose any information of a confidential nature received from the other relating to the subject of this AGREEMENT or the business affairs of the other both during and after this - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 9 - AGREEMENT. This undertaking will not apply to any such information which is or falls into the public domain through no fault of the recipient or is lawfully received from a third party or independently developed by the recipient's staff without reverence to the discloser's information. 14.2 Neither party shall make any public announcement in relation to this AGREEMENT without the prior written approval of the other or as otherwise required by law. 15. Indemnification 15.1 Except to the extent the other is negligent or commits an act of wilful misconduct or in default of the terms hereof, each party shall hold the other party harmless from responsibility or liability for damages related to the PRODUCTS or COMPONENTS of this AGREEMENT arising from the fault of such party, its affiliated companies, or its agents or employees. 16. Notices 16.1 All notices to be given with respect to this AGREEMENT shall be in writing and shall be deemed effectively given: a. when delivered personally; b. seven calendar days after being deposited in the mail, registered or certified mail, return receipt requested; c. when telecopied or faxed, receipt acknowledged; or d. when telexed, confirmed; addressed as set forth below, or to such other address that either party designates by written notice to the other party; ENZO: Enzo Diagnostics, Inc. 575 Fifth Avenue, 18th Floor New York, New York 10017 Attn: Dr. Barbara E. Thalenfeld Vice President, Scientific Affairs Fax No.: (212) 856-0878 - 10 - AMERSHAM: AMERSHAM INTERNATIONAL PLC Amersham Place Little Chalfont Buckinghamshire HP7 9NA England Att: Company Secretary Fax No.: (494) 542266 17. Governing Law 17.1 This Agreement is made under and shall be governed by the laws of the State of New York. 18. Waiver 18.1 Waiver by ENZO or AMERSHAM of any provision of this AGREEMENT shall not be deemed a waiver of future compliance therewith and such provision as well as all other provisions hereunder shall remain in full force and effect. 19. Compliance with Laws 19.1 Each party will comply with all United States laws, ordinances and regulations properly applicable to the manufacture, sale and distribution of the PRODUCTS described herein. 20. Headings and Numbers 20.1 All Headings and Numbers of the clauses of this AGREEMENT are inserted for convenience only and shall not affect any construction or interpretation of this AGREEMENT. 21. Severability 21.1 IN THE EVENT that any clause of this Agreement shall be found to be void or unenforceable, such finding shall not be construed to render any other clause of this AGREEMENT either void or unenforceable, and all other clauses shall remain in full force and effect unless the clause(s) which is/are invalid or unenforceable shall substantially affect the rights or obligations granted to or undertaken by either party. - 11 - 22. Entirety 22.1 THIS AGREEMENT together with the EXHIBITS attached hereto embodies the entire understanding between AMERSHAM and ENZO, and there are no contracts or prior drafts of the Agreement, understandings, conditions, warranties or representations, oral or written, express or implied, with reference to the subject matter hereof which are not merged herein. Except as otherwise specifically stated, no modification here to shall be of any force or effect unless (1) reduced to writing and signed by both parties hereto, and (2) expressly referred to as being modifications of this AGREEMENT. IN WITNESS, WHEREOF, the parties have caused this AGREEMENT to be executed by their duly authorized representatives. ENZO DIAGNOSTICS, INC. AMERSHAM INTERNATIONAL PLC By: By: ------------------------------ ---------------------------------- Elazar Rabbani ((name)) Title: President Title: Commercial Director --------------------------- --------------------------- Date: Feb 16 1995 Date: 21. 2. 95 --------------------------- --------------------------- * * * * * * * - 12 - EXHIBIT A Enzo Diagnostics, Inc. Issued Patents U.S. Patents ================================================================================ Grant of Patent Patent Number Title/Inventor Issue Date - -------------------------------------------------------------------------------- 4,687,732 Visualization Polymers and Their Aug. 18, 1987 Application to Diagnostic Medicine David C. Ward et al. - -------------------------------------------------------------------------------- 4,707,352 Method of Radioactively Labeling Nov. 17, 1987 Diagnostic and Therapeutic Agents Containing a Chelating Group Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,707,440 Nucleic Acid Hybridization Assay and Nov. 17, 1987 Detectable Molecules Useful in Such Assay Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,711,955 Modified Nucleotides and Methods of Dec. 8, 1987 Preparing and Using Same David C. Ward et al. - -------------------------------------------------------------------------------- 4,746,604 Specific Binding Assays Utilizing A Viable May 24, 1988 Cell as a Label Solomon Mowshowitz - -------------------------------------------------------------------------------- 4,755,458 Composition and Method for the Detection Jul. 5, 1988 of the Presence of a Polynucleotide Sequence of Interest Elazar Rabbani et al. - -------------------------------------------------------------------------------- 4,767,609 Therapeutic and Diagnostic Processes Aug. 30, 1988 Using Isotope Transfer to Chelator-Target Recognition Molecule Conjugate Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,772,548 Radioisotopicassay Using Isotope Transfer Sep. 20, 1988 to Chelator-Target Recognition Molecule Conjugate Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,843,122 Detectable Molecules, Method of June 27, 1989 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,849,208 Detectable Molecules, Method of Jul. 18, 1989 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- - 1 - ================================================================================ Grant of Patent Patent Number Title/Inventor Issue Date - -------------------------------------------------------------------------------- 4,849,505 Detectable Molecules, Method of Jul. 18, 1989 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,868,103 Analyte Detection by Means of Energy Sep. 19, 1989 Transfer Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,889,798 Heterologous System for the Detection of Dec. 26, 1989 Chemically Labeled DNA and other Biological Materials Providing a Receptor or Target Moiety Thereon Elazar Rabbani - -------------------------------------------------------------------------------- 4,894,325 Hybridization Method for the Detection of Jan. 16, 1990 Genetic Material Dean Engelhardt et al. - -------------------------------------------------------------------------------- 4,900,659 Nucleotide Sequence Composition and Feb. 13, 1990 Method for Detection for Neissera Gonorrhoeae and Method for Screening for a Nucleotide Sequence that is Specific for a Genetically Distinct Group Andrew Lo et al. - -------------------------------------------------------------------------------- 4,943,523 Detectable Molecules, Method of Jul. 24, 1990 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,952,685 Detectable Molecules, Method of Aug. 28, 1990 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 4,987,065 In Vivo Labelling of Polynucleotide Jan. 22, 1991 Sequences Jannis G. Stavrianopoulos et al. - -------------------------------------------------------------------------------- 4,994,373 Method and Structures Employing Feb. 19, 1991 Chemically-Labelled Polynucleotide Probes Jannis G. Stavrianopoulos et al. - -------------------------------------------------------------------------------- 5,002,885 Detectable Molecules, Method of Mar. 26, 1991 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 5,013,831 Detectable Molecules, Method of May 7, 1991 Preparation and Use Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 5,024,933 Method and Kit for Sample Adherence to June 18, 1991 Test Substrate Huey-Lang Yang et al. - -------------------------------------------------------------------------------- 5,061,076 Time-Resolved Fluorometer Oct. 29, 1991 Ian Hurley - -------------------------------------------------------------------------------- - 2 - ================================================================================ Grant of Patent Patent Number Title/Inventor Issue Date - -------------------------------------------------------------------------------- 5,082,830 End Labeled Nucleotide Probe Jan. 21, 1992 Christine L. Brakel et al. - -------------------------------------------------------------------------------- 5,175,269 Compound and Detectable Molecules Dec. 29, 1992 Having An Oligo- or Polynucleotide with Modifiable Reactive Group Jannis G. Stavrianopoulos - -------------------------------------------------------------------------------- 5,241,060 Base Moiety-Labeled Detectable Nucleotide Aug. 31, 1993 Dean Engelhardt et al. - -------------------------------------------------------------------------------- 5,260,433 Saccharide Specific Binding System Nov. 9, 1993 Labeled Nucleotides Dean Engelhardt et al. - -------------------------------------------------------------------------------- 5,288,609 Capture Sandwich Hybridization Method Feb. 22, 1994 and Composition Dean Engelhardt et al. - -------------------------------------------------------------------------------- 5,328,824 Methods of Using Labeled Nucleotides Jul. 12, 1994 David C. Ward - -------------------------------------------------------------------------------- Allowed claims (195-267) transmitted on Feb. 6, 1995 to Amersham under Confidientiality Agreement ================================================================================ - 3 - ================================================================================ Patent Number Publication Date (Country) Title/Inventor of Patent Grant - -------------------------------------------------------------------------------- 560 651 (Australia) Modified Nucleotides and Methods of Oct. 16, 1987 (16 Preparing and Using Same yr. term began Apr. David C. Ward et al. 13, 1982) - -------------------------------------------------------------------------------- 1 219 824 (Canada) Modified Nucleotides and Methods of Mar. 31, 1987 Preparing and Using Same David C. Ward et al. - -------------------------------------------------------------------------------- 1 223 831 (Canada) Modified Nucleotides, Methods of Jul. 7, 1987 Preparing and Utilizing and Compositions Containing the Same Dean L. Engelhardt et al. - -------------------------------------------------------------------------------- EP 0 285 057 B1 Modified Nucleotides, Methods of May 10, 1988 Preparing and Utilizing and Compositions Containing the Same Dean L. Engelhardt et al. - -------------------------------------------------------------------------------- EP 0 063 879 B1 Modified Nucleotides and Methods of Nov. 23, 1989 Preparing and Using Same David C. Ward et al. - -------------------------------------------------------------------------------- 1,237,369 Visualization Polymers and Their May 31, 1988 Application to Diagnostic Medicine David C. Ward et al. - -------------------------------------------------------------------------------- 1,254,525 Kit for Terminally Chemically Labeling May 23, 1989 DNA Christine L. Brakel et al. - -------------------------------------------------------------------------------- 1,256,023 Method of Radioactively Labeling June 20, 1989 Diagnostic and Therapeutic Agents Containing a Chelating Group Jannis Stavrianopoulos - -------------------------------------------------------------------------------- 1,260,368 Composition and Method for the Sept. 26, 1989 Detection of the Presence of a Polynucleotide Sequence of Interest Elazar Rabbani et al. - -------------------------------------------------------------------------------- 1,260,372 Hybridization Method for the Sept. 26, 1989 Detection of Genetic Materials Elazar Rabbani et al. ================================================================================ - 4 - ================================================================================ Patent Number Publication Date (Country) Title/Inventor of Patent Grant - -------------------------------------------------------------------------------- 1,268,115 Method and Composition for Detecting April 24, 1990 Analyte Moieties Solomon Mowshowitz - -------------------------------------------------------------------------------- 1,281,283 (Canada) Method for Detecting an Analyte Moiety Mar. 12, 1991 by Means of Signal Localization Elazar Rabbani - -------------------------------------------------------------------------------- 1,285,330 Analyte Detection by Means of Energy June 25, 1991 Transfer Jannis Stavrianopoulos et al. - -------------------------------------------------------------------------------- 1,288,811 Assay Method Utilizing Polynucleotide Nov. 3, 1987 Sequences Robert Pergolizzi et al. - -------------------------------------------------------------------------------- EP 0 133 473 B1 In Vivo Labelling of Polynucleotide March 23, 1994 Sequences Jannis Stavrianopoulos et al. - -------------------------------------------------------------------------------- EP 0 173 339 B1 Composition and Method for the Jan. 22, 1992 Detection of the Presence of a Polynucleotide Sequence of Interest Elazar Rabbani et al. - -------------------------------------------------------------------------------- EP 0 212 546 B1 Method for Labeling Polynucleotide Apr. 1, 1992 Sequences Jannis Stavrianopoulos et al. - -------------------------------------------------------------------------------- 1,295,559 Method for Labeling Polynucleotide Feb. 11, 1992 Sequences Jannis Stavrianopoulos et al. - -------------------------------------------------------------------------------- 1,299,073 Nucleotide Sequence Composition Method Apr. 21, 1992 for Detection of Neisseria gonorrhoeae and Method (Canada) for Screening for a Nucleotide Sequence that is Specific for a Genetically Distinct Group Andrew Lo & Huey-Lang Yang - -------------------------------------------------------------------------------- 1,309,672 Methods and Structures Employing Non- Nov. 3, 1992 Radioactive Chemically-Labeled Polynucleotide Probes Jannis Stavrianopoulos ================================================================================ - 5 - ================================================================================ Patent Number Publication Date (Country) Title/Inventor of Patent Grant - -------------------------------------------------------------------------------- 1,314,503 Detectable Moelcules, Method of March 16, 1993 Preparation And Use Jannis Stavrianopoulos - -------------------------------------------------------------------------------- 1,314,810 Heterologous System for the Detection March 23, 1993 of Chemically-Labeled DNA and Other Biological Materials Providing a Receptor or Target Moiety Thereon Elazar Rabbani - -------------------------------------------------------------------------------- EP 0 242 527 B1 Analyte Detection by Means of Energy May 13, 1992 Transfer Jannis Stavrianopoulos et al. - -------------------------------------------------------------------------------- 1,315,222 Polynucleotide Probes and a Method for March 30, 1993 Their Preparation David Mao et al. - -------------------------------------------------------------------------------- 0 149 654 B1 Detecting Agent Carrying Polymer Sep. 9, 1992 Having Multiple Units of Visualization Monomer David C. Ward et al. - -------------------------------------------------------------------------------- EP 0 097 373 B1 Modified Nucleotides, Methods of Oct. 7, 1992 Preparing and Utilizing and Compositions Containing the Same Dean L. Engelhardt et al. - -------------------------------------------------------------------------------- EP 0 212 670 B1 Method for Detecting an Analyte Moiety Nov. 4, 1992 by Means of Signal Localization Elazar Rabbani - -------------------------------------------------------------------------------- EP 0 117 440 B1 Method and Structures Employing Apr. 7, 1993 Chemically-Labelled Polynucleotide Probes Jannis G. Stavrianopoulos et al. - -------------------------------------------------------------------------------- EP 0 244 860 B1 Polynucleotide Probes and a Method Apr. 7, 1993 for their Preparation David T. Mao et al. ================================================================================ EP 0 343 424 B1 Method and Kit for Sample Adherence Apr. 21, 1993 to Test Substrate Huey-Lang Yang et al. ================================================================================ - 6 - ================================================================================ Patent Number Publication Date (Country) Title/Inventor of Patent Grant - -------------------------------------------------------------------------------- EP 0 159 719 B1 Hybridization Method for the Jun. 30, 1993 Detection of Genetic Material Dean Engelhardt et al. - -------------------------------------------------------------------------------- EP 0 122 614 B1 Kit for Terminally Chemically Jul. 14, 1993 Labelling DNA Christine Brakel - -------------------------------------------------------------------------------- EP 0 150 844 B1 Method of Radioactively Labeling Jul. 28, 1993 Diagnostic and Therapeutic Agents Containing a Chelating Group Jannis Stavrianpoulos - -------------------------------------------------------------------------------- 0 237 737 B1 A Composition Specific for Neisseria Sep. 8, 1993 Gonorrhoea Andrew Lo et al. ================================================================================ - 7 - EXHIBIT B: Products and Transfer Price Paid by Amersham * - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 1 - * PRICE INDEX 1995 IN SITU HYBRIDIZATION ASSAY SYSTEMS
Cat. No. Product Quantity Price BioPap(TM) Kits for Detection of HPV on Cervical Smear Specimens 32881 BioPap Human papillomavirus DNA Assay for Cervical Smears 20 test kit $ 345.00 32892 BioPap Human papillomavirus DNA Typing Assay for Cervical Specimens (Types 6/11, 16/18, 31/33/51 10 test kit 305.00 32883 BioPap Human Papillomavirus DNA Typing Assay Certival Specimen Transport Kit for 10 specimen 35.00 PathoGene(R) Kits for Detection of HPV on Formalin-fixed, Paraffin-embedded Tissue Sections 32879 PathoGene in situ Screening Assay for Human Papillomavirus 20 test kit 425.00 32895 PathoGene in situ Typing Assay for Human Papillomavirus (Types 6/11, 16/18, 31/33/51) 10 test kit 305.00 32877 PathoGene DNA Probe Assay for Identification of Human Papillomavirus (Types 6/11, 16/18, 31/33/51 20 test kit 525.00 32878 PathoGene HPV 18 DNA Probe Reagent 1 ml 140.00 PathoGene(R) Kits for Detection of Infectious Agents on Formalin-fixed, Paraffin-embedded Tissue Sections Peroxidase-AEC Substrate Detection Kits 32871 PathoGene DNA Probe Assay for Identification of Adenovirus 32872 PathoGene DNA Probe Assay for Identification of Cytomegalovirus 20 test kit 235.00 32873 PathoGene DNA Probe Assay for Identification of Epstein-Barr Virus 20 test kit 260.00 32874 PathoGene DNA Probe Assay for Identification of Hepatitis B Virus 20 test kit 235.00 32875 PathoGene DNA Probe Assay for Identification of Herpes Simplex Virus 20 test kit 235.00 32876 PathoGene DNA Probe Assay for Identification of Chlamydia trachomatis 20 test kit 235.00 Peroxidase-DAB Substrate Detection Kits 32861 PathoGene DNA Probe Assay for identification of 20 test kit 235.00 32862 PathoGene DNA Probe Assay for identification of 20 test kit 260.00 32863 PathoGene DNA Probe Assay for identification of 20 test kit 235.00 32864 PathoGene DNA Probe Assay for identification of 20 test kit 235.00 32865 PathoGene DNA Probe Assay for identification of 20 test kit 235.00 32866 PathoGene DNA Probe Assay for identification of 20 test kit 235.00
- ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 2 - Alkaline Phosphatase-BCIP/NBT Substrate Detection Kit 32851 PathoGene DNA Probe Assay for identification of Adenovirus 20 test kit $250.00 32852 PathoGene DNA Probe Assay for identification of Cytomegalovirus 20 test kit 275.00 32853 PathoGene DNA Probe Assay for identification of Epstein-Barr Virus 20 test kit 250.00 32854 PathoGene DNA Probe Assay for identification of Hepatitus B Virus 20 test kit 250.00 32855 PathoGene DNA Probe Assay for identification of Herpes Simplex Virus 20 test kit 250.00 32856 PathoGene DNA Probe Assay for identification of Chlamydia trachomatis 20 test kit 250.00 IN SITU HYBRIDIZATION ASSAY SYSTEMS Cat. No. Product Quantity Price 32870 Peroxidase-ABC Detection Kit (ready-to-use) 20 test kit 95.00 32860 Peroxidase-ABC Detection Kit (ready-to-use) 20 test kit 95.00 32850 Alkaline Phosphate-BCIP/NBT (ready-to-use) 20 test kit 105.00 32700 Enhanced in situ Detection Kit, alkaline phosphatase 20 test kit 195.00 32600 Enhanced in situ Detection Kit, peroxidase 20 test kit 195.00 IN SITU HYBRIDIZATION ASSAY SYSTEMS Cat. No. Product Quantity Price 46305 Dot Blot Hybridization and Detection Assay Kit 1 kit 750.00 46305C Dot Blot Hybridization and Detection Assay Kit, Control DNA Pack 1 kit 170.00 46307 Dot Blot Hybridization and Detection Assay Kit, CMV Control DNA Pack 1 kit 135.00 46308 Dot Blot Hybridization and Detection Assay Kit, HBV Control DNA Pack 1 kit 135.00 44300 Dot Blot Manifold 1 unit 425.00 46330 HIV-1 Microplate Hybridization Assay 96 test kit 625.00 46331 SK 38K/SK 39 Oligonucleotide pair complementary to HIV-1 gag region 5 nanomoles each 175.00 46340 MTB Microplate Hybridization Assay 96 test kit 625.00 46341 MTB 10/MTB 11 Oligonucleotide pair complementary to MTB 5 nanomoles each 175.00 46350 HBV Microplate Hybridization Assay 96 test kit 625.00 46351 HBO1/HBO2 Oligonucleotide pair complementary to HBV core region 5 nanomoles each 175.00 46352 HBV Serum Specimen Preparation Kit for 96 specimens 50.00 46353 HBV Enhanced Microplate Hybridization Assay for 96 specimens 700.00 46354 HBV Serum Specimen Titration Standards for 4 assay determinations 50.00 46360 HIV-2 Microplate Hybridization Assay 96 test kit 625.00 46361 B306/VB310 Oligonucleotide pair complementary to HIV-2 5 nanomoles each 175.00
- 3 - BIOPROBE(R) LABELED PROBES Cat. No. Product Quantity Price 40834 Adenovirus 80ul $175.00 40835 Cytomegalovirus 80ul 205.00 40836 Epstein-Barr Virus 80ul 175.00 40837 Hepatitus B Virus 80ul 175.00 40838 Herpes Simplex Virus 80ul 175.00 40839 Chlamydia trachomatis 80ul 175.00 40840 Lambda 80ul 175.00 40841 pBR322 (negative DNA control) 80ul 75.00 40842 Hepatitis A Virus 80ul 175.00 40843 Mycoplasma pneymoniae 80ul 175.00 40845 SV40 80ul 175.00 40846 Campylobacter jejuni 80ul 175.00 40847 JC Virus 80ul 175.00 40848 BK Virus 80ul 175.00 40849 Blur 8 (human alu repeat) (positive DNA control) 80ul 75.00 40714 c-Ha-ras (activated, human) 80ul 220.00 40717 c-Myc (human) 80ul 220.00 40718 N-Myc (human) 80ul 220.00 BIOPROBE(R) LABELING SYSTEMS FOR NUCLEIC ACIDS Cat. No. Product Quantity Price 42803 Nick Translation System (containing Bio II-dUTP) for 10u DNA 230.00 42804 Nick Translation System (to be used with nucleotide of choice) for 10u DNA 105.00 42809 Terminal Labeling Kit for 10u DNA 285.00 42810 Random Priming Kit (containing Bio 11-dUTP) for 10u DNA 230.00 42813 BioBridge Labeling System for 8u DNA 295.00 42814 BioBridge Lebaling Molecule for 8u DNA 210.00 42807 RNA Labeling System - T3/T7 for 20 reactions (1u each) 330.00 42808 RNA Labeling System - SP6 for 20 reactions (1u each) 330.00 BIOPROBE(R) LABELING SYSTEMS FOR NUCLEIC ACIDS - BIOTINYLATED NUCLEOTIDES Cat. No. Product Quantity Price 42806 Bio-11dUTP (0.3 mM) 22.5 nanomoles 225.00 42806-50 Bio-11dUTP (1.0 mM) 50.0 nanomoles 285.00 42811 Bio-16dUTP (0.3 mM) 22.5 nanomoles 230.00 42811-50 Bio-16dUTP (1.0 mM) 50.0 nanomoles 285.00 42816 Bio-11dCTP (0.3 mM) 22.5 nanomoles 225.00 42816-50 Bio-11dCTP (1.0 mM) 50.0 nanomoles 285.00 42819 Bio-7-dATP (0.3 mM) 22.5 nanomoles 225.00 42819-50 Bio-71dATP (1.0 mM) 50.0 nanomoles 285.00
- 4 - 42812 Bio-AP3-dCTP (0.3 mM) 22.5 nanomoles $230.00 42815 Bio-11-CTP (20 mM) 1u mole 385.00 42801 Bio-11-CTP (20 mM) 1u mole 385.00 42817 Allylamine UTP (20 mM) 400 nanomoles 230.00 DETEK(R) SIGNAL GENERATING SYSTEMS Cat. No. Product Quantity Price 43818* DETEK I-f for 200 slides 180.00 43861* IgG fraction rabbit anti-biotin 0.4 ml 210.00 43805* DETEK-fav 5 ml 110.00 43820* DETEK-hrp Kit 00 ml working solution or 150.00 40 membranes (100 cm2 each) 43822* DETEK-alk Kit 500 ml working solution or 225.00 40 membranes (100 cm2 each) 42823* DETEK Enhancer Kit for 20 slides 135.00 43825 Peroxidase Substrate Kit (AEC) 300 ml working solution 90.00 43826 Peroxidase Substrate Kit (DAB) 300 ml working solution 90.00 43827 Alkaline Phospharase Substrate Kit (NBT/BCIP) 400 ml working solution 160.00 43406 ENZOITIN(R)Biotinylating Reagent 100 mg 150.00 GLASS FIBER FILTERS Cat. No. Product Quantity Price 44524 Disc (24 min diameter) 400/box 60.00 44525 Disc (25 min diameter) 400/box 60.00 44101 Rectangle (10.25 cm x 25.4 cm) 100/box 120.00
* These PRODUCTS are designated for nucleic acid detection - 5 - EXHIBIT C: AMERSHAM AFFILIATES Australia: Amersham Australia Pty Ltd 16 Anella Avenue Castle Hill, Sydney NSW 2154 Australia Belgium: Amersham Belgium NV/SA Ottergemseteenweg 644 Z 9000 gent Belgium Canada: Amersham Canada Ltd 1166 South Service Road West Oakville Ontario L6L 5T7 Canada Denmark: Amersham Denmark ApS Blokken 11 DK-3460 Birkerod Denmark France: Amersham France SA 12 Avenue des Tropiques ZA Courtaboeuf 91944 Les Ulis France Germany: Amersham Buchler GmbH & Co KG Geschaftsbereich Life Science Gieselweg 1 D - 38110 Braunschweig Germany Hong Kong: Amersham Far East Trading Ltd Suite 1001-7 Sun Hung Kai Centre 30 Harbour Road Wanchai, Hong Kong Italy: Amersham Italia S.r.L Via Quintilliano 30 20138 Milano Italy - 1 - Japan: Amersham KK Tokyo Toyama Kaikan 1-3 Hakusan 5-Chome Bunkyo-Ku Tokyo 112 Japan Netherlands: Amersham Nederland B.V Amerikastraat 3a 5232 BE's Hertogenbosch Netherlands Norway: Amersham Denmark Aps Norway Branch Baerumsveien 373 PO Box 170 N-1346 Gjettum Norway Russia: Amersham International plc Moscow Office Tverskaya 22A, 5th Floor Moscow 103050, Russia Spain: Amersham Iberica S.A Alfonso Gomex 38-4a 28037 Madrid Spain Sweden: Amersham Sweden AB Parkvagen 4B 171 23 Solna Sweden Switzerland: Amersham Rahn Dorflistrasse 120 CH-8050 Zurich Switzerland USA: Amersham North America 2636 South Clearbrook Drive Arlington Heights Illinois 60005 - 2 - EXHIBIT D: Component and transfer price paid by Enzo * - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 1 - EXHIBIT E: Component 1 and transfer price paid by Enzo * Patents licensed to Amersham International ================================================================================ Country Patent Number Inventor - -------------------------------------------------------------------------------- UK/Belgium/France/Germany/Italy/ EPO 116454 Whitehead T.P. et al. Netherlands/Sweden/Switzerland - -------------------------------------------------------------------------------- Australia 575552 Whitehead T.P. et al. - -------------------------------------------------------------------------------- Canada 1217121 Whitehead T.P. et al. - -------------------------------------------------------------------------------- Finland 76380 Whitehead T.P. et al. - -------------------------------------------------------------------------------- Japan 1649 482 Whitehead T.P. et al. - -------------------------------------------------------------------------------- New Zealand 207095 Whitehead T.P. et al. - -------------------------------------------------------------------------------- South Africa 84/0909 Whitehead T.P. et al. - -------------------------------------------------------------------------------- USA 4598044 Whitehead T.P. et al. - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Europe 120376 Renz M - -------------------------------------------------------------------------------- USA 5053326 Renz M - -------------------------------------------------------------------------------- Japan 1634268 Renz M ================================================================================ - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 1 - Exhibit F: * - ---------- * The information omitted is confidential and has been filed separately with the Commission pursuant to Rule 406. - 1 - Exhibit G: Product Safety Regulations - -------------------------- US: OSHA Hazard Communication Standards UK: Chemical (Hazardous Information and Packaging) Japan: Poisonous and Deleterious Substance Control Law - 1 -